JNCE Insider Trading Activity and SEC Form 4 Filings
JNCE insider trading summary
No open-market insider purchases or sales of Jounce Therapeutics, Inc. (JNCE) have been reported on SEC Form 4 in the past 12 months.
Latest JNCE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 4, 2023 | Richard Murray | Director | Sell | $73K (39,228 @ $1.85) |
| Mar 14, 2023 | Tang Capital Management LLC | 10% Owner | Buy | $21K (20,286 @ $1.02) |
| Mar 14, 2023 | Tang Capital Partners LP | 10% Owner | Buy | $21K (20,286 @ $1.02) |
| Mar 14, 2023 | Kevin C Tang | 10% Owner | Buy | $21K (20,286 @ $1.02) |
| Mar 13, 2023 | Tang Capital Partners LP | 10% Owner | Buy | $65K (65,701 @ $0.99) |
| Mar 13, 2023 | Kevin C Tang | 10% Owner | Buy | $65K (65,701 @ $0.99) |
| Mar 13, 2023 | Tang Capital Management LLC | 10% Owner | Buy | $65K (65,701 @ $0.99) |
| Jan 10, 2023 | Hugh M Cole | Chief Operating Officer | Sell | $10K (9,182 @ $1.12) |
| Jan 10, 2023 | Richard Murray | CEO and President | Sell | $28K (24,879 @ $1.12) |
| Jan 10, 2023 | Elizabeth Trehu | Chief Medical Officer | Sell | $6K (5,126 @ $1.12) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.